RecruitingNCT07151898
PET/CT for Trop2 ADC Response Evaluation NSCLC
Evaluation of Treatment Response to Trop2 ADC by 68Ga-MY6349 PET/CT in NSCLC
Sponsor
The First Affiliated Hospital of Xiamen University
Enrollment
50 participants
Start Date
May 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in NSCLC patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- adult patients (aged 18 years or order)
- histologically or cytologically confirmed metastatic NSCLC previously treated with systemic therapy, supported by imaging (e.g. CT, MRI), tumor markers, or pathology reports
- presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1
- willingness to undergo serial 68Ga-MY6349 PET/CT scans before and during Trop2-ADC therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee
Exclusion Criteria2
- Evidence of significantly impaired hepatic or renal function
- Estimated life expectancy of less than 3 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TEST68Ga-MY6349 PET/CT
Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging at baseline and following two and/or four cycles of Trop2-ADC therapy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07151898
Related Trials
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT052833304 locations
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
NCT0662083527 locations
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143207 locations
Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE
NCT075591231 location
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
NCT041141361 location